We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company
News

PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company

PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company
News

PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PolyTherics Initiates New Research and Option Agreement with Top Ten Pharmaceutical Company"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to its collaborator. The study will utilise PolyTherics’ considerable expertise in the adaptation of antibody fragments for therapeutic use.
 
PolyTherics receives an upfront licence fee as well as payment on achievement of pre-defined programme milestones. The collaborator receives an option to negotiate for a license to the collaboration intellectual property to develop and commercialise novel products. Further details of the agreement terms were not disclosed.

PolyTherics has substantial expertise in the targeted modification of biologic compounds with therapeutic potential. Through its platform of site specific poly(ethylene glycol) (PEG)-based technologies, the Company systematically optimises the performance of biologics for administration as parenteral drugs. PolyTherics will be attending the BIO International Convention in Chicago between 3 and 6 May 2010 and is available to meet companies interested in its technologies.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: “With large pharma companies clearly committed to developing biologics as drugs, we are seeing considerable interest in technologies that serve the need for optimized pharmacokinetic half-life. This new feasibility study builds on PolyTherics’ proven achievements applying its PEGylation technologies to antibody fragments to enhance therapeutic performance”.

Advertisement